Flagship explainer
What drives Lyra Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$28.9M | FY2025 |
| |
| Income before tax | −$28.9M | FY2025 |
|
| Operating income | −$31M | FY2025 |
|
| $398000 | FY2025 |
| |
| Ending assets | $36.1M | FY2025 |
|
| Beginning assets | $66.3M | FY2024 |
|
| −$10.7M | FY2025 |
| |
| $11.6M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001327273-26-000003